GlassScriptPhysician profile
Bryce C Heitman
NPI 1336325646
$1,949.64
in general payments reported to CMS, 2019-2025
28 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $71.74 · 2021: $88.67 · 2022: $554 · 2023: $312 · 2024: $389 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $319.44 | 2021-2025 | |
| Novo Nordisk INC | $229.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.43 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $146.95 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $137.70 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $115.80 | 2022-2025 | |
| Lilly USA, LLC | $114.57 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.51 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $82.17 | 2019-2022 | |
| Amgen INC. | $68.94 | 2022-2024 | Otezla, Repatha, Evenity |
| Otsuka America Pharmaceutical, INC. | $51.34 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $49.25 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $45.36 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.60 | 2022 | |
| Glaxosmithkline, LLC. | $36.83 | 2019-2024 | Trelegy Ellipta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $30.10 | 2023-2025 | Austedo, Austedo Xr |
| Tris Pharma INC | $27.73 | 2019 | |
| Dexcom, INC. | $18.78 | 2025 | Dexcom G6 Transmitter |
| Smith+Nephew, INC. | $18.52 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.39 | 2023 | Eliquis |
| Abbott Laboratories | $15.87 | 2022 | |
| Ardelyx, INC. | $15.34 | 2024 | Ibsrela |
| Ultragenyx Pharmaceutical INC. | $15.24 | 2020 | |
| Insulet Corporation | $14.65 | 2025 | Omnipod |
| Idorsia Pharmaceuticals US INC | $13.48 | 2023 | Quviviq |
| Boston Scientific Corporation | $13.42 | 2022 | |
| Agios Pharmaceuticals, INC. | $13.22 | 2023 | Pyrukynd |
| Sanofi Pasteur INC. | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryce Heitman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.